Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016754 · ClinicalTrials.gov registry record
Heart Failure Optimization Study
A clinical trial, sponsored by Zoll Medical Corporation.
- Completed
- Registry status
- 602
- Enrollment target
NCT03016754 is a clinical trial that has completed, run by Zoll Medical Corporation. The registered enrollment target is 602 participants.
The verdict
NCT03016754 has completed, sponsored by Zoll Medical Corporation.
- COMPLETED
- Registry status
- 602 participants
- Enrollment target
Study Summary
This study is designed as a multi-center prospective observational study of newly diagnosed Heart Failure (HF) patients to test the hypothesis that additional Ejection Fraction (EF) recovery occurs between 90 and 180 days as Guideline Directed Medical Therapy (GDMT) is achieved. Although the study doesn't start until day 90, all eligible, consenting patients will be entered into a registry at the start of wearable cardioverter defibrillator (WCD) use. The pre-study registry will allow us to collect early (90 day) outcomes and data in those patients who are likely to be eligible for the study at day 90, or are eligible, but refuse the study at day 90.
Interventions
- DEVICE Wearable Cardioverter Defibrillator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2022-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03016754
The ClinicalTrials.gov registry entry for NCT03016754 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zoll Medical Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Wearable Cardioverter Defibrillator is the first listed.
NCT03016754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03016754 about?
NCT03016754 is a clinical study titled "Heart Failure Optimization Study". This study is designed as a multi-center prospective observational study of newly diagnosed Heart Failure (HF) patients to test the hypothesis that additional Ejection Fraction (EF) recovery occurs between 90 and 180 days as Guideline Directed Medical Therapy (GDMT) is achieved. Although the study d...
What is the current status of trial NCT03016754?
This trial is currently completed. The enrollment target is 602 participants. The study started on 2017-03-01. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT03016754?
The interventions under investigation include: Wearable Cardioverter Defibrillator (DEVICE).
Who is sponsoring clinical trial NCT03016754?
This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.